Overview

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Status:
Recruiting

Trial end date:
2027-08-12

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

iTeos Therapeutics

Treatments:

Dostarlimab